



Mebiopharm Co., Ltd.
ARK Hills Executive Tower 8th Floor
1-14-5 Akasaka, Minato-ku,
Tokyo 107-0052 Japan
Phone +81-3-6426-5766 FAX +81-3-3505-2663

Mebiopharm Announces Technology Evaluation Agreement with Merck Serono to explore new tumor specific formulations

TOKYO, JAPAN –October 20th, 2015–Mebiopharm, a Tokyo-based company, announced today that they have entered into a Technology Evaluation Agreement with Merck Serono, biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Under the agreement, Mebiopharm will formulate several compounds of Merck Serono using their tumor specific formulation technology. Merck Serono will then evaluate such formulated compounds for their potential use in further drug discovery and development. Upon promising results, the parties will negotiate a license agreement, in which Merck Serono will utilize Mebiopharm’s technology to discover and develop pharmaceutical candidates.

Mebiopharm Co., Ltd.

A pharmaceutical bioventure company established in 2002 originating from University of Tokyo asset and listed on TOKYO AIM market, established with Tokyo Stock Exchange and London Stock Exchange, as the first listed company (delisted in June 2013 by our own intention).

Established a drug delivery nano technology, DDS formulation attached with tissue to be targeted selective ligand molecule and carrying out a clinical Phase 2 study in US and Europe in oncology. Also a development for Nano DDS Generic formulation has been moving forward by applying an accumulated knowledge, technology and know-how, so Mebio develops a business model combined with new drug and generic drug development, and aiming for a leading company in the world by Drug Delivery System technology.

October 20, 2015

Tadashi Fujisawa
CEO, Mebiopharm Co., Ltd.

Contact

Kumiko Suzuki
Public Relations Office
Mebiopharm Co., Ltd.
k.suzuki@mebiopharm.com
Tel: +81-3-6426-5766